Drug firm Zydus Cadila today said it has crossed $1 billion in revenues for the financial year ended March 31, 2011.
Though the company's results are yet to be audited, the estimations are based on company's management information system (MIS), Zydus Cadila said in a statement.
The journey to the billion had started in 2007, soon after the group had crossed its goal of posting a turnover of $400 million, the company added.
"This has been the result of an all-round effort in terms of strengthening existing businesses, building new capabilities and venturing into new geographies," Zydus Cadila CMD Pankaj R Patel said.
The key markets of the US, France, Spain, Japan, Brazil, and South Africa have contributed to this goal by growing at more than 40 per cent, he added.
The company said its India formulations business, with over 300 new product launches has been the mainstay of the operations.
"Foray into specialised areas like dermatology, nutraceuticals, hepatology and rheumatology with the setting up of new speciality divisions has helped the group create new inroads in the Indian pharma market," the company said.
